Loading...
XTAI1795
Market cap2.14bUSD
Dec 23, Last price  
263.50TWD
1D
1.15%
1Q
-2.77%
Jan 2017
339.90%
Name

Lotus Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XTAI:1795 chart
P/E
17.03
P/S
4.12
EPS
15.47
Div Yield, %
1.30%
Shrs. gr., 5y
1.92%
Rev. gr., 5y
21.41%
Revenues
16.96b
+15.89%
606,822,000590,184,000532,209,000503,153,000658,481,0002,310,021,0005,521,937,0005,902,566,0006,423,760,0006,428,894,0009,174,740,00010,728,583,00012,649,189,00014,632,772,00016,957,971,000
Net income
4.11b
+35.91%
3,117,00015,051,000-38,403,000-193,234,00011,882,000-442,127,000103,949,000-134,041,0007,685,00099,476,000662,807,0001,026,796,0001,403,371,0003,020,757,0004,105,626,000
CFO
1.61b
-56.60%
89,499,00059,194,000-76,294,000-54,453,000-95,837,000-1,032,408,0001,077,573,0001,233,001,000592,293,000796,978,000302,809,0001,948,682,000119,662,0003,719,418,0001,614,207,000
Dividend
Aug 05, 20244.64745 TWD/sh
Earnings
Mar 12, 2025

Profile

Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.
URL
https://www.lotuspharm.com.tw/
IPO date
Dec 13, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
16,957,971
15.89%
14,632,772
15.68%
12,649,189
17.90%
Cost of revenue
12,059,066
10,524,992
10,319,525
Unusual Expense (Income)
NOPBT
4,898,905
4,107,780
2,329,664
NOPBT Margin
28.89%
28.07%
18.42%
Operating Taxes
997,299
919,455
466,648
Tax Rate
20.36%
22.38%
20.03%
NOPAT
3,901,606
3,188,325
1,863,016
Net income
4,105,626
35.91%
3,020,757
115.25%
1,403,371
36.67%
Dividends
(906,227)
(506,058)
(92,005)
Dividend yield
1.27%
0.79%
0.37%
Proceeds from repurchase of equity
598
1,356,296
BB yield
0.00%
-5.42%
Debt
Debt current
1,883,203
274,859
1,677,134
Long-term debt
9,954,026
8,748,919
4,816,335
Deferred revenue
45,326
65,915
85,957
Other long-term liabilities
665,566
607,744
726,737
Net debt
7,018,037
4,871,159
4,586,246
Cash flow
Cash from operating activities
1,614,207
3,719,418
119,662
CAPEX
(410,568)
(3,069,391)
(1,615,750)
Cash from investing activities
(3,249,290)
(4,656,148)
(1,576,843)
Cash from financing activities
1,402,672
1,261,731
1,663,191
FCF
(2,079,309)
3,701,418
(1,691,333)
Balance
Cash
1,770,880
1,983,383
1,605,495
Long term investments
3,048,312
2,169,236
301,728
Excess cash
3,971,293
3,420,980
1,274,764
Stockholders' equity
10,254,183
7,736,885
4,487,768
Invested Capital
25,658,023
19,307,386
16,714,077
ROIC
17.35%
17.70%
12.30%
ROCE
16.14%
17.72%
12.74%
EV
Common stock shares outstanding
262,024
261,684
256,685
Price
272.00
10.57%
246.00
152.31%
97.50
21.88%
Market cap
71,270,528
10.71%
64,374,264
157.22%
25,026,788
28.49%
EV
78,288,565
69,245,423
29,613,034
EBITDA
6,109,544
5,044,646
3,089,045
EV/EBITDA
12.81
13.73
9.59
Interest
557,397
382,460
296,839
Interest/NOPBT
11.38%
9.31%
12.74%